4.26 – Seven Transmembrane G Protein-Coupled Receptors: Insights for Drug Design from Structure and Modeling
暂无分享,去创建一个
Frank E. Blaney | N. Barton | Stephen L. Garland | B. Tehan | Ian David Wall | I. Wall | F. Blaney | B. Tehan | S. Garland | N. Barton | Ian D. Wall
[1] L. Pardo,et al. Benzimidazole derivatives. 3. 3D-QSAR/CoMFA model and computational simulation for the recognition of 5-HT(4) receptor antagonists. , 2002, Journal of medicinal chemistry.
[2] P Herzyk,et al. Automated method for modeling seven-helix transmembrane receptors from experimental data. , 1995, Biophysical journal.
[3] N. Mochizuki,et al. Development of novel EDG3 antagonists using a 3D database search and their structure-activity relationships. , 2002, Journal of medicinal chemistry.
[4] M Rarey,et al. Detailed analysis of scoring functions for virtual screening. , 2001, Journal of medicinal chemistry.
[5] D Eisenberg,et al. Hydrophobicity and amphiphilicity in protein structure , 1986, Journal of cellular biochemistry.
[6] A. Lomize,et al. The transmembrane 7-alpha-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints. , 1997, Biophysical journal.
[7] K Prendergast,et al. Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. , 1994, Chemistry & biology.
[8] Philip M. Dean,et al. Design criteria for molecular mimics of fragments of the β-turn. 1. Cα atom analysis , 1999, J. Comput. Aided Mol. Des..
[9] A. Krogh,et al. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. , 2001, Journal of molecular biology.
[10] Giampiero Spalluto,et al. Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example. , 2005, Trends in pharmacological sciences.
[11] R. Riek,et al. NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[12] K. Jacobson,et al. The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family. , 2000, Bioorganic & medicinal chemistry letters.
[13] André Chollet,et al. Biophysical approaches to G protein-coupled receptors: Structure, function and dynamics , 1999, J. Comput. Aided Mol. Des..
[14] J Hoflack,et al. Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. , 1992, Journal of medicinal chemistry.
[15] Alan Wise,et al. Target validation of G-protein coupled receptors. , 2002, Drug discovery today.
[16] S. Amara,et al. Transmembrane topology mapping using biotin-containing sulfhydryl reagents. , 1998, Methods in enzymology.
[17] A. Fliri,et al. Biological spectra analysis: Linking biological activity profiles to molecular structure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[18] T. Schwartz,et al. Steric hindrance mutagenesis versus alanine scan in mapping of ligand binding sites in the tachykinin NK1 receptor. , 1998, Molecular pharmacology.
[19] G. Klebe,et al. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.
[20] D. Rognan,et al. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.
[21] H. Khorana,et al. Structure and function in rhodopsin. Cysteines 65 and 316 are in proximity in a rhodopsin mutant as indicated by disulfide formation and interactions between attached spin labels. , 1996, Biochemistry.
[22] K. R. Woods,et al. A computer program for predicting protein antigenic determinants. , 1983, Molecular immunology.
[23] J. Javitch. Probing structure of neurotransmitter transporters by substituted-cysteine accessibility method. , 1998, Methods in enzymology.
[24] Jérôme Hert,et al. Comparison of Fingerprint-Based Methods for Virtual Screening Using Multiple Bioactive Reference Structures , 2004, J. Chem. Inf. Model..
[25] J. Javitch,et al. Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice. , 1995, Biochemistry.
[26] Y. Burstein,et al. Messenger RNA of opsin from bovine retina: isolation and partial sequence of the in vitro translation product. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[27] Jeff Morris,et al. Further Development of Reduced Graphs for Identifying Bioactive Compounds , 2003, J. Chem. Inf. Comput. Sci..
[28] Didier Rognan,et al. Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.
[29] W. Boyar,et al. Residues 21–30 within the Extracellular N-terminal Region of the C5a Receptor Represent a Binding Domain for the C5a Anaphylatoxin* , 1998, The Journal of Biological Chemistry.
[30] E. Bradley,et al. Design of a gene family screening library targeting G-protein coupled receptors. , 2004, Journal of molecular graphics & modelling.
[31] T. Schwartz,et al. Conversion of agonist site to metal-ion chelator site in the beta(2)-adrenergic receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[32] K. Neve,et al. Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations. , 1998, Molecular pharmacology.
[33] L. Pardo,et al. Optimization of the pharmacophore model for 5-HT7R antagonism. Design and synthesis of new naphtholactam and naphthosultam derivatives. , 2003, Journal of medicinal chemistry.
[34] H. Steinhoff,et al. Determination of interspin distances between spin labels attached to insulin: comparison of electron paramagnetic resonance data with the X-ray structure. , 1997, Biophysical journal.
[35] H. Khorana,et al. A collision gradient method to determine the immersion depth of nitroxides in lipid bilayers: application to spin-labeled mutants of bacteriorhodopsin. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[36] W. Hubbell,et al. Recent advances in site-directed spin labeling of proteins. , 1998, Current opinion in structural biology.
[37] D. Middlemiss,et al. Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. , 2000, Journal of medicinal chemistry.
[38] Roger Crossley. The design of screening libraries targeted at G-protein coupled receptors. , 2004, Current topics in medicinal chemistry.
[39] R. Rudolph,et al. The N-terminal fragment of human parathyroid hormone receptor 1 constitutes a hormone binding domain and reveals a distinct disulfide pattern. , 2000, Biochemistry.
[40] K. Marx,et al. Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction. , 1997, Biochemistry.
[41] D. Donnelly. The arrangement of the transmembrane helices in the secretin receptor family of G‐protein‐coupled receptors , 1997, FEBS letters.
[42] I. Sylte,et al. Molecular dynamics of dopamine at the D2 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[43] J. Thornton,et al. Beta-turns and their distortions: a proposed new nomenclature. , 1990, Protein engineering.
[44] J. Ballesteros,et al. Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment. , 1999, Biochemistry.
[45] T. Schwartz,et al. Locating ligand-binding sites in 7TM receptors by protein engineering. , 1994, Current opinion in biotechnology.
[46] Xueliang Fang,et al. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.
[47] The complex of human Gs protein with the beta 3 adrenergic receptor: a computer-aided molecular modeling study. , 1994, Journal of molecular graphics.
[48] A. Kerlavage,et al. Molecular biology of adrenergic and muscarinic cholinergic receptors. A perspective. , 1989, Biochemical pharmacology.
[49] T. Schwartz,et al. Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor , 1995, Nature.
[50] H. Hamm,et al. The 2.0 Å crystal structure of a heterotrimeric G protein , 1996, Nature.
[51] H. Khorana,et al. Structural features of the C-terminal domain of bovine rhodopsin: a site-directed spin-labeling study. , 1999, Biochemistry.
[52] Martin Ebeling,et al. An Automated System for the Analysis of G Protein-Coupled Receptor Transmembrane Binding Pockets: Alignment, Receptor-Based Pharmacophores, and Their Application , 2005, J. Chem. Inf. Model..
[53] Ruben Abagyan,et al. Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[54] J. Manzanares,et al. Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1, 3-dioxoperhydroimidazo[1,5-alpha]pyridine: a selective 5-HT1A receptor agonist. , 1996, Journal of medicinal chemistry.
[55] Bernhard Pfeiffer,et al. Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. , 2005, Chemical reviews.
[56] Manuel C. Peitsch. Membrane protein models , 1997 .
[57] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[58] D. Sibley,et al. Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. , 2000, Molecular pharmacology.
[59] C. Humblet,et al. MODELING RHODOPSIN, A MEMBER OF G‐PROTEIN COUPLED RECEPTORS, BY COMPUTER GRAPHICS. INTERPRETATION OF CHEMICAL SHIFTS OF FLUORINATED RHODOPSINS , 1992, Photochemistry and photobiology.
[60] Mette M. Rosenkilde,et al. Molecular Mechanism of AMD3100 Antagonism in the CXCR4 Receptor , 2004, Journal of Biological Chemistry.
[61] C. Derian,et al. Design and evaluation of potent peptide‐mimetic PAR1 antagonists , 2003 .
[62] P Jeffrey Conn,et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. , 2003, Molecular pharmacology.
[63] J Ellis,et al. Structure/function relationships of muscarinic acetylcholine receptors. , 1993, Life sciences.
[64] Valerie J. Gillet,et al. SPROUT: A program for structure generation , 1993, J. Comput. Aided Mol. Des..
[65] David E. Clark,et al. Enhancing the Hit-to-Lead Properties of Lead Optimization Libraries , 2000, J. Chem. Inf. Comput. Sci..
[66] C Altenbach,et al. Structural features and light-dependent changes in the sequence 306-322 extending from helix VII to the palmitoylation sites in rhodopsin: a site-directed spin-labeling study. , 1999, Biochemistry.
[67] D. Donnelly,et al. Predicting the point at which transmembrane helices protrude from the bilayer: a model of the antenna complexes from photosynthetic bacteria. , 1993, Protein engineering.
[68] Jonathan A Javitch,et al. Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method , 1995, Neuron.
[69] Gerhard Hessler,et al. Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.
[70] Didier Rognan,et al. Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.
[71] P. Willett,et al. Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures. , 2004, Organic & biomolecular chemistry.
[72] M. López-Rodríguez,et al. CB1 and CB2 cannabinoid receptor binding studies based on modeling and mutagenesis approaches. , 2005, Mini reviews in medicinal chemistry.
[73] L. Pardo,et al. 3-D-QSAR/CoMFA and recognition models of benzimidazole derivatives at the 5-HT(4) receptor. , 2001, Bioorganic & medicinal chemistry letters.
[74] D K Jones-Hertzog,et al. Use of recursive partitioning in the sequential screening of G-protein-coupled receptors. , 1999, Journal of pharmacological and toxicological methods.
[75] Konstantin V. Balakin,et al. Structure-Based versus Property-Based Approaches in the Design of G-Protein-Coupled Receptor-Targeted Libraries , 2003, J. Chem. Inf. Comput. Sci..
[76] Terri L. Gilbert,et al. The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins , 1993, Neuron.
[77] B. Kobilka,et al. Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. , 1995, The Journal of biological chemistry.
[78] Mark S.P. Sansom,et al. Hinges, swivels and switches: the role of prolines in signalling via transmembrane α-helices , 2000 .
[79] L. Pardo,et al. On the use of the transmembrane domain of bacteriorhodopsin as a template for modeling the three-dimensional structure of guanine nucleotide-binding regulatory protein-coupled receptors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[80] F E Blaney,et al. Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists. , 2001, Journal of medicinal chemistry.
[81] P. Woollard,et al. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. , 2005, Journal of medicinal chemistry.
[82] J. Fahrenkrug,et al. Proposed arrangement of the seven transmembrane helices in the secretin receptor family. , 1998, Receptors & channels.
[83] M. Karplus,et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .
[84] S. Frye. Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. , 1999, Chemistry & biology.
[85] Leonardo Pardo,et al. Computational Model of the Complex between GR113808 and the 5-HT4 Receptor Guided by Site-Directed Mutagenesis and the Crystal Structure of Rhodopsin , 2001, J. Comput. Aided Mol. Des..
[86] David A. Cosgrove,et al. Lead Hopping Using SVM and 3D Pharmacophore Fingerprints , 2005, J. Chem. Inf. Model..
[87] Patrick M Sexton,et al. Photoaffinity scanning in the mapping of the peptide receptor interface of class II G protein—coupled receptors , 2004, Journal of peptide science : an official publication of the European Peptide Society.
[88] J Hoflack,et al. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. , 1991, Molecular pharmacology.
[89] F. Blaney,et al. Evidence for the proximity of the extreme N-terminus of the neurokinin-2 (NK2) tachykinin receptor to Cys167 in the putative fourth transmembrane helix. , 2004, Biochemistry.
[90] P. Gmeiner,et al. Rationally based efficacy tuning of selective dopamine d4 receptor ligands leading to the complete antagonist 2-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213). , 2001, Journal of medicinal chemistry.
[91] J. Ballesteros,et al. Dopamine D4/D2 receptor selectivity is determined by A divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments. , 1999, Molecular pharmacology.
[92] M. Heel,et al. Single-particle electron cryo-microscopy: towards atomic resolution , 2000, Quarterly Reviews of Biophysics.
[93] M. López-Rodríguez,et al. Synthesis and structure-activity relationships of a new model of arylpiperazines. 2. Three-dimensional quantitative structure-activity relationships of hydantoin-phenylpiperazine derivatives with affinity for 5-HT1A and alpha 1 receptors. A comparison of CoMFA models. , 1997, Journal of medicinal chemistry.
[94] Michael M. Hann,et al. RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..
[95] Øyvind Edvardsen,et al. A database of mutants and effects of site‐directed mutagenesis experiments on G protein‐coupled receptors , 1996, Proteins.
[96] J. Mason,et al. New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. , 1999, Journal of medicinal chemistry.
[97] T. Steitz,et al. Identifying nonpolar transbilayer helices in amino acid sequences of membrane proteins. , 1986, Annual review of biophysics and biophysical chemistry.
[98] Christopher A Reynolds,et al. Toward the active conformations of rhodopsin and the β2‐adrenergic receptor , 2004, Proteins.
[99] Gerhard Klebe,et al. Ligand-supported homology modeling of g-protein-coupled receptor sites: models sufficient for successful virtual screening. , 2004, Angewandte Chemie.
[100] Shaomeng Wang,et al. An Extensive Test of 14 Scoring Functions Using the PDBbind Refined Set of 800 Protein-Ligand Complexes , 2004, J. Chem. Inf. Model..
[101] S. Dowell,et al. Complex chimeras to map ligand binding sites of GPCRs. , 2003, Protein engineering.
[102] T. Klabunde,et al. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.
[103] Shay Bar-Haim,et al. G protein-coupled receptors: in silico drug discovery in 3D. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[104] Kurt Kristiansen,et al. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. , 2004, Pharmacology & therapeutics.
[105] G. Costantino,et al. Homology modeling of metabotropic glutamate receptors. (mGluRs) structural motifs affecting binding modes and pharmacological profile of mGluR1 agonists and competitive antagonists. , 1996, Journal of medicinal chemistry.
[106] K. Chapman,et al. Combinatorial synthesis of 3-(amidoalkyl) and 3-(aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors. , 2002, Bioorganic & medicinal chemistry letters.
[107] M. Karplus,et al. Enhanced sampling in molecular dynamics: use of the time-dependent Hartree approximation for a simulation of carbon monoxide diffusion through myoglobin , 1990 .
[108] William R. Taylor,et al. Ab initio modelling of the N-terminal domain of the secretin receptors , 2003, Comput. Biol. Chem..
[109] Maya Topf,et al. PREDICT modeling and in‐silico screening for G‐protein coupled receptors , 2004, Proteins.
[110] Martyn G. Ford,et al. Selecting Screening Candidates for Kinase and G Protein-Coupled Receptor Targets Using Neural Networks , 2002, J. Chem. Inf. Comput. Sci..
[111] J. Pin,et al. Mutagenesis and Modeling of the GABAB Receptor Extracellular Domain Support a Venus Flytrap Mechanism for Ligand Binding* , 1999, The Journal of Biological Chemistry.
[112] Leonardo Pardo,et al. Synthesis and Structure−Activity Relationships of a New Model of Arylpiperazines. 8.1 Computational Simulation of Ligand−Receptor Interaction of 5-HT1AR Agonists with Selectivity over α1-Adrenoceptors , 2005 .
[113] J. Ballesteros,et al. Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice. , 1996, Biochemistry.
[114] P. Malherbe,et al. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. , 2003, Molecular pharmacology.
[115] Renxiao Wang,et al. Comparative evaluation of 11 scoring functions for molecular docking. , 2003, Journal of medicinal chemistry.
[116] S. Trumpp-Kallmeyer,et al. This is not a G protein-coupled receptor. , 1993, Trends in pharmacological sciences.
[117] Yoshihisa Inoue,et al. Mutagenesis and the Molecular Modeling of the Rat Angiotensin II Receptor (AT1) (*) , 1995, The Journal of Biological Chemistry.
[118] R. Henderson,et al. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. , 1990, Journal of molecular biology.
[119] K. M. Smith,et al. Novel software tools for chemical diversity , 1998 .
[120] L. Pardo,et al. Synthesis and structure-activity relationships of a new model of arylpiperazines. Study of the 5-HT(1a)/alpha(1)-adrenergic receptor affinity by classical hansch analysis, artificial neural networks, and computational simulation of ligand recognition. , 2001, Journal of medicinal chemistry.
[121] Caterina Bissantz,et al. Conformational Changes of G Protein‐Coupled Receptors During Their Activation by Agonist Binding , 2003, Journal of receptor and signal transduction research.
[122] P. Wyatt,et al. 2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: Identification, stereochemistry and initial SAR. , 2005, Bioorganic & Medicinal Chemistry Letters.
[123] R. Elber,et al. Modeling side chains in peptides and proteins: Application of the locally enhanced sampling and the simulated annealing methods to find minimum energy conformations , 1991 .
[124] Robert J. Jilek,et al. "Lead hopping". Validation of topomer similarity as a superior predictor of similar biological activities. , 2004, Journal of medicinal chemistry.
[125] Robert P Bywater,et al. Recognition of privileged structures by G-protein coupled receptors. , 2004, Journal of medicinal chemistry.
[126] Gebhard F. X. Schertler,et al. Arrangement of rhodopsin transmembrane α-helices , 1997, Nature.
[127] L. Prézeau,et al. Mapping the Agonist-binding Site of GABAB Type 1 Subunit Sheds Light on the Activation Process of GABABReceptors* , 2000, The Journal of Biological Chemistry.
[128] J. Holbrook,et al. Bioinformatics and type II G-protein-coupled receptors. , 2001, Biochemical Society transactions.
[129] Manuel Peitsch,et al. Probing the Structure and Function of the Tachykinin Neurokinin-2 Receptor through Biosynthetic Incorporation of Fluorescent Amino Acids at Specific Sites* , 1996, The Journal of Biological Chemistry.
[130] M. López-Rodríguez,et al. Synthesis and structure-activity relationships of a new model of arylpiperazines. 3.1 2-[omega-(4-arylpiperazin-1-yl)alkyl]perhydropyrrolo- [1,2-c]imidazoles and -perhydroimidazo[1,5-a]pyridines: study of the influence of the terminal amide fragment on 5-HT1A affinity/selectivity. , 1997, Journal of medicinal chemistry.
[131] Erik Nordling,et al. Generalization of a targeted library design protocol: application to 5-HT7 receptor ligands. , 2004, Journal of chemical information and computer sciences.
[132] J. Baldwin. The probable arrangement of the helices in G protein‐coupled receptors. , 1993, The EMBO journal.
[133] I. Forbes,et al. CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. , 2003, Journal of medicinal chemistry.
[134] K. Bleicher,et al. Parallel solution- and solid-phase synthesis of spiropyrrolo-pyrroles as novel neurokinin receptor ligands. , 2002, Bioorganic & medicinal chemistry letters.
[135] Robert S. Pearlman,et al. Metric Validation and the Receptor-Relevant Subspace Concept , 1999, J. Chem. Inf. Comput. Sci..
[136] J. Kew,et al. Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor* , 2003, The Journal of Biological Chemistry.
[137] D. J. Price,et al. Assessing scoring functions for protein-ligand interactions. , 2004, Journal of medicinal chemistry.
[138] J. Klein-Seetharaman,et al. Structural features and light-dependent changes in the sequence 59-75 connecting helices I and II in rhodopsin: a site-directed spin-labeling study. , 1999, Biochemistry.
[139] Patrick M. Sexton,et al. International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors , 2002, Pharmacological Reviews.
[140] W Patrick Walters,et al. A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance , 2004, Proteins.
[141] Gerhard Klebe,et al. Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures , 1994, J. Chem. Inf. Comput. Sci..
[142] Gebhard F. X. Schertler,et al. Projection structure of rhodopsin , 1993, Nature.
[143] Todd J. A. Ewing,et al. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..
[144] Leonardo Pardo,et al. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. , 2005, Journal of medicinal chemistry.
[145] M. López-Rodríguez,et al. Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2, 5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2, 5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1A af , 1999, Journal of medicinal chemistry.
[146] J. Ballesteros,et al. The first transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. , 2000, Biochemistry.
[147] Valerie J. Gillet,et al. SPROUT: Recent developments in the de novo design of molecules , 1994, J. Chem. Inf. Comput. Sci..
[148] T. Mielke,et al. Electron crystallography reveals the structure of metarhodopsin I , 2004, The EMBO journal.
[149] Yong‐Chul Kim,et al. Application of a novel design paradigm to generate general nonpeptide combinatorial scaffolds mimicking beta turns: synthesis of ligands for somatostatin receptors. , 2003, Bioorganic & medicinal chemistry.
[150] D. Kostrewa,et al. Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.
[151] S. Sasaki,et al. Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. , 1998, Journal of medicinal chemistry.
[152] S. Dabbs,et al. Synthesis, biological activity, and molecular modeling of selective 5-HT(2C/2B) receptor antagonists. , 1996, Journal of medicinal chemistry.
[153] D. Guédin,et al. Molecular modeling of the GABA/GABA(B) receptor complex. , 2001, Journal of medicinal chemistry.
[154] John P. Overington,et al. The prediction and orientation of alpha-helices from sequence alignments: the combined use of environment-dependent substitution tables, Fourier transform methods and helix capping rules. , 1994, Protein engineering.
[155] J. Ballesteros,et al. A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. , 1998, Biochemistry.
[156] D E Nichols,et al. Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping. , 1996, Journal of medicinal chemistry.
[157] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[158] Philip M. Dean,et al. A validation study on the practical use of automated de novo design , 2002, J. Comput. Aided Mol. Des..
[159] C. Strader,et al. Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. , 1989, The Journal of biological chemistry.
[160] S. O. Smith,et al. NMR constraints on the location of the retinal chromophore in rhodopsin and bathorhodopsin. , 1995, Biochemistry.
[161] P. Portoghese,et al. From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. , 2001, Journal of medicinal chemistry.
[162] S. Tamura,et al. Clinically validated peptides as templates for de novo peptidomimetic drug design at G-protein-coupled receptors. , 2003, Current opinion in pharmacology.
[163] Parallel solution- and solid-phase synthesis of spirohydantoin derivatives as neurokinin-1 receptor ligands. , 2002, Bioorganic & medicinal chemistry letters.
[164] S. Sprang,et al. The structure of the G protein heterotrimer Giα1 β 1 γ 2 , 1995, Cell.
[165] B. E. Evans,et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.
[166] Mark Whittaker,et al. The selection and design of GPCR ligands: from concept to the clinic. , 2004, Combinatorial chemistry & high throughput screening.
[167] C. Hutchison,et al. Mutagenesis at a specific position in a DNA sequence. , 1978, The Journal of biological chemistry.
[168] S. Nakanishi,et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor , 2000, Nature.
[169] L. Miller,et al. Molecular Approximation between a Residue in the Amino-terminal Region of Calcitonin and the Third Extracellular Loop of the Class B G Protein-coupled Calcitonin Receptor* , 2004, Journal of Biological Chemistry.
[170] T. Schwartz,et al. Partial agonism through a zinc-Ion switch constructed between transmembrane domains III and VII in the tachykinin NK(1) receptor. , 2000, Molecular pharmacology.
[171] Darren V. S. Green,et al. Where Are the GaPs? A Rational Approach to Monomer Acquisition and Selection , 2000, J. Chem. Inf. Comput. Sci..
[172] G. W. Price,et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. , 2003, Molecular pharmacology.
[173] R. Wolf,et al. Homology Modeling of the Transmembrane Domain of the Human Calcium Sensing Receptor and Localization of an Allosteric Binding Site* , 2004, Journal of Biological Chemistry.
[174] C. Venkatachalam,et al. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. , 2003, Journal of molecular graphics & modelling.
[175] G. Liapakis,et al. Constitutive Activation of the β2 Adrenergic Receptor Alters the Orientation of Its Sixth Membrane-spanning Segment* , 1997, The Journal of Biological Chemistry.
[176] J. Javitch,et al. A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[177] L. Pardo,et al. Design, synthesis and pharmacological evaluation of 5-hydroxytryptamine(1a) receptor ligands to explore the three-dimensional structure of the receptor. , 2002, Molecular pharmacology.
[178] L. Pardo,et al. 5-HT(4) receptor antagonists: structure-affinity relationships and ligand-receptor interactions. , 2002, Current topics in medicinal chemistry.
[179] S. Jois,et al. Design of β-turn Based Therapeutic Agents , 2003 .
[180] M. Delgado,et al. Design and synthesis of S-(-)-2-[[4-(napht-1-yl)piperazin-1-yl]methyl]-1,4-dioxoperhydropyrrolo[1,2-a]pyrazine (CSP-2503) using computational simulation. A 5-HT1A receptor agonist. , 2003, Bioorganic & medicinal chemistry letters.
[181] T. Schwartz,et al. Construction of a High Affinity Zinc Switch in the -Opioid Receptor (*) , 1996, The Journal of Biological Chemistry.
[182] Nirmala Bhogal,et al. The first de novo-designed antagonists of the human NK(2) receptor. , 2005, Journal of medicinal chemistry.
[183] R. Neubig,et al. NMR Structure of the Second Intracellular Loop of the α2A Adrenergic Receptor: Evidence for a Novel Cytoplasmic Helix†,‡ , 2002 .
[184] V. Hruby. Design in topographical space of peptide and peptidomimetic ligands that affect behavior. A chemist's glimpse at the mind--body problem. , 2001, Accounts of chemical research.
[185] Philip M. Dean,et al. Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design , 1997, J. Comput. Aided Mol. Des..
[186] Konstantin V. Balakin,et al. Property-Based Design of GPCR-Targeted Library , 2002, J. Chem. Inf. Comput. Sci..
[187] A. Watts. NMR of drugs and ligands bound to membrane receptors. , 1999, Current opinion in biotechnology.
[188] H. Khorana,et al. Structural features and light-dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: a site-directed spin-labeling study. , 1996, Biochemistry.
[189] Philip M. Dean,et al. A branch-and-bound method for optimal atom-type assignment in de novo ligand design , 1998, J. Comput. Aided Mol. Des..
[190] R. Doolittle,et al. A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.
[191] P. Beroza,et al. A rapid computational method for lead evolution: description and application to alpha(1)-adrenergic antagonists. , 2000, Journal of medicinal chemistry.
[192] Robert J. Jilek,et al. Topomers: A Validated Protocol for Their Self-Consistent Generation , 2004, J. Chem. Inf. Model..
[193] Neera Borkakoti,et al. Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. , 2003, Bioorganic & medicinal chemistry letters.
[194] Øyvind Edvardsen,et al. tGRAP, the G-protein coupled receptors mutant database , 2002, Nucleic Acids Res..
[195] E. Eliopoulos,et al. Three-dimensional modelling of G protein-linked receptors. , 1990, Trends in pharmacological sciences.
[196] T. Frimurer,et al. Structure of the integral membrane domain of the GLP1 receptor , 1999, Proteins.
[197] H Gobind Khorana,et al. Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. , 2003, Advances in protein chemistry.
[198] J. Fahrenkrug,et al. A Model of the Receptors in the VIP Receptor Family , 1998, Annals of the New York Academy of Sciences.
[199] A H Beth,et al. Molecular distances from dipolar coupled spin-labels: the global analysis of multifrequency continuous wave electron paramagnetic resonance data. , 1997, Biophysical journal.
[200] T. Guo,et al. Privileged structure-based combinatorial libraries targeting G protein-coupled receptors. , 2003, Assay and drug development technologies.
[201] John Bradshaw,et al. Similarity Searching Using Reduced Graphs , 2003, J. Chem. Inf. Comput. Sci..
[202] Didier Rognan,et al. High-Throughput Modeling of Human G-Protein Coupled Receptors: Amino Acid Sequence Alignment, Three-Dimensional Model Building, and Receptor Library Screening , 2004, J. Chem. Inf. Model..
[203] A. Watts,et al. Photoreceptor rhodopsin: structural and conformational study of its chromophore 11‐cis retinal in oriented membranes by deuterium solid state NMR , 1998, FEBS letters.
[204] P J Goodford,et al. COMPOUNDS DESIGNED TO FIT A SITE OF KNOWN STRUCTURE IN HUMAN HAEMOGLOBIN , 1976, British journal of pharmacology.
[205] Philip M. Dean,et al. Design criteria for molecular mimics of fragments of the β-turn. 2. Cα–Cβ bond vector analysis , 1999, J. Comput. Aided Mol. Des..
[206] Edgar Jacoby,et al. Chemogenomics knowledge-based strategies in drug discovery. , 2003, Drug news & perspectives.
[207] J Hoflack,et al. Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. , 1995, The EMBO journal.